Sino Biopharmaceutical (HKG:1177) unit Beijing Tide Pharmaceutical's Second-Generation Flurbiprofen Patch obtained marketing approval from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.
The approval is for the indications of analgesia and anti-inflammatory treatment for osteoarthritis, shoulder periarthritis, tendinitis and tenosynovitis, peritendinitis, lateral epicondylitis, muscle pain, and swelling and pain due to trauma.
The product was also granted a four-year data protection period by the regulator.